Experimental drugs addition to treatment of multidrug-resistant TB shows promising resultsJune 4th, 2009 - 5:48 pm ICT by ANI
London, June 4 (ANI): Interim results from an ongoing phase 2 trial of the experimental drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) seem to be encouraging, say researchers.
Experts running the trial have revealed that the addition of TMC207 for eight weeks to a 5-drug background regimen, in patients with MDR-TB, resulted in a significant increase in the proportion of patients achieving a negative sputum culture and a shorter time to sputum culture conversion compared with the background regimen alone.
“The results of this study are highly encouraging news for the treatment of tuberculosis,” the New England Journal of Medicine quoted Dr. Peter Donald, Professor Emeritus, Stellenbosch University in Capetown, South Africa, as saying.
“Not only is this an agent with a radically different means of action, but it shows potential to shorten the treatment of tuberculosis in the foreseeable future, something the tuberculosis community has been hoping for years,” he added.
The researchers are investigating TMC207 as part of a combination therapy for the treatment of MDR-TB. The results reported are from the first stage of a two-stage Phase II randomised placebo-controlled trial.
The researchers said that they randomised 47 hospitalised patients with newly diagnosed multidrug-resistant pulmonary TB to receive TMC207 daily for 2 weeks, followed by 200 mg three-times weekly for 6 weeks, or placebo in combination with a standardized 5-drug background second-line antituberculosis regimen.
Six subjects discontinued the study prematurely. This first stage was conducted in South Africa, where the prevalence of MDR-TB is particularly high.
The results of bacterial culture of sputum showed more patients were TB culture-negative at 8 weeks in the TMC207 group, 47.6 per cent versus 8.7 per cent in the placebo group.
The researchers also found that TMC207 reduced the time to culture conversion.
Most adverse events were mild to moderate and only nausea occurred more frequently with TMC207 than with placebo.
One subject in each treatment group experienced a serious adverse event, neither of which was considered to be related to the study medication.
The data obtained validate ATP synthase as a viable target for the treatment of TB.
“The nearly half a million estimated new cases of MDR-TB annually highlights the urgent need for a paradigm shift in the way this disease is being tackled. The development of TMC207 is a tribute to the dedication of our scientists, to innovation and to the commitment of our company to accelerating the development of new drug regimens for tuberculosis,” said Roger Pomerantz, President, Tibotec Research & Development.
The safety and efficacy of TMC207 are being further evaluated in ongoing and future trials. (ANI)
- 'Time to scale up work on TB control' - Jan 24, 2012
- 90-minute TB test not a game changer for India - Aug 29, 2011
- Awareness programmes mark World Tuberculosis Day in Delhi - Mar 24, 2011
- India, China account for 45 percent multi-drug resistant TB - Aug 27, 2010
- WHO calls for dealing with multi-drug resistant microbes - Apr 07, 2011
- Central team to probe drug resistant TB cases in Mumbai - Jan 17, 2012
- Berlin 2010: TB, HIV and Lung Health: From research and innovation to solutions - Nov 02, 2010
- Faster body metabolism renders TB drugs ineffective - Jan 04, 2012
- TB causing half million annual deaths in South-East Asia: WHO - Mar 22, 2012
- India battles staggering tuberculosis burden (March 24 is World TB Day) - Mar 23, 2011
- Standard re-treatment regimen for TB 'failing' in developing world - Mar 16, 2011
- Novel TB test may provide results quickly, efficiently - May 08, 2009
- Cabinet approves scaling up services of management of drug resistant tuberculosis - Mar 03, 2011
- Online course in tuberculosis treatment launched - Oct 15, 2009
- Regulatory Conference Shows The Way Forward From Lessons Learnt In The Past - Aug 20, 2010
Tags: bacterial culture, capetown south africa, combination therapy, encouraging news, england journal of medicine, experimental drug, hospitalised patients, interim results, journal of medicine, new england journal, new england journal of medicine, placebo group, professor emeritus, promising results, pulmonary tb, resistant tb, resistant tuberculosis, sputum culture, stellenbosch university, treatment of tuberculosis